Business Context and Reporting Period
Company: American BriVision (Holding) Corporation (Note: Input metadata references "ABVC BIOPHARMA, INC.", but the filing text identifies the registrant as American BriVision (Holding) Corporation).
Filing Type: Form 8-K (Current Report)
Reporting Period: September 17, 2019 (Earliest event reported: September 11, 2019)
Event: Entry into material definitive agreements for the sale of unregistered securities.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance. No revenue, profit, cash flow, or margin data is provided in this document.
- Total Capital Raised: $257,500
- Instrument: Convertible Promissory Notes
- Interest Rate: 20% per annum
- Maturity: One year from issuance date
- Conversion Price: Lower of $0.50 per share or 70% of the per share offering price of a future public equity offering exceeding $10,000,000.
- Ownership Cap: Conversion limited to prevent beneficial ownership exceeding 4.99%.
Material Changes
The filing details the following capital raising activities:
- September 11, 2019: Sold one convertible promissory note with a principal amount of $70,000 to one accredited investor.
- September 16, 2019: Sold two additional convertible promissory notes with an aggregate principal amount of $187,500 to two additional accredited investors.
The filing text does not provide comparative financial data or prior period metrics to assess material changes in operating performance.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to issue the three Notes as soon as practicable. The financing is structured to potentially convert into equity upon a future public offering exceeding $10 million.
Risks and Contingencies:
- Dilution Risk: The conversion price mechanism (70% of future offering price) could result in significant dilution to existing shareholders if a public offering occurs.
- Debt Obligation: The Company has incurred a direct financial obligation with a high interest rate (20%) due within one year if not converted.
- Unregistered Securities: The securities were sold pursuant to exemptions from registration under the Securities Act.
Investor Verification Checklist
- Verify the current cash position of American BriVision (Holding) Corporation to assess ability to service the 20% interest on the $257,500 debt.
- Confirm the total number of shares currently issued and outstanding to calculate the potential dilution impact of the 4.99% ownership cap and conversion mechanics.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 10.2) for specific adjustment provisions and default terms.
- Investigate the Company's progress toward a public equity offering exceeding $10,000,000, which triggers the alternative conversion price.